Glaxo's Advair Rejected by US FDA for an Added Use (Update1) - Bloomberg
Glaxo's Advair Rejected by US FDA for an Added Use (Update1)Bloomberg - Aug 8, 20078 (Bloomberg) — GlaxoSmithKline Plc failed to win US approval to market the strongest dose of the asthma inhaler Advair Diskus, the company's top-selling …
Read full story